Stephen Gould
Associate Director, Senior Scientist, Translational Oncology
"I am passionate about my work and believe that the ability to successfully bring drugs from paper to pill requires two basic elements: hard work and an environment that demands that the difficult questions be asked at each step of the process. Genentech provides an environment where this approach leads to amazing advances in the treatment of disease."
- 7
years at Genentech - 5
publications (2010-12) - 5
awards & honors
I joined Genentech in 2006 after seven years in the Boston biotech sector, four of which were spent in a productive collaboration with scientists here at Genentech. The decision to become an East Coast transplant was driven by my passion to take small molecule drugs from concept to patients, and to do so in an environment driven by science and the desire to have a dramatic impact on patient outcome.
As a transition point between the bench and the clinic, the translational oncology group is focused on providing data that determines the relative efficacy of new agents and correlates efficacy with target inhibition and drug exposures to help inform clinical strategy.
Featured Publication
Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma.
Science 2009 Oct 23; 326(5952): 572-4.
Yauch RL, Dijkgraaf GJ, Alicke B, Januario T, Ahn CP, Holcomb T, Pujara K, Stinson J, Callahan CA, Tang T, Bazan JF, Kan Z, Seshagiri S, Hann CL, Gould SE, Low JA, Rudin CM, de Sauvage FJ.
View Abstract on PubMed
